Review Open access

Herbal nanoparticles in the treatment of neurodegeneration: from molecular mechanisms to therapeutic translation

D. Mittal Pavitra Solanki G. K. Jain V. Jhawat Prashant Kesharwani Rohit Dutt Saahil Arora R. Singh

Sep 2026 · 3 Biotech · Vol 16 · 1 citation · 176 references

Medicine

TL;DR

This review critically summarizes recent advances in herbal nanoformulations, emphasizing disease-specific molecular targets, BBB-targeting strategies, comparative nanocarrier systems, pharmacokinetic optimization, intracellular trafficking, and translational challenges.

DOI PubMed Semantic Scholar

Read PDF

Similar papers

Review Open access Sep 2026

Efficacy of Curcumin in Neurodegenerative Diseases: From Pharmacokinetic Barriers to Advanced Delivery Systems

Background and Objectives: The main neurodegenerative diseases (NDs)—Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS)—represent a growing global health burden with no available disease-modifying therapies. Curcumin, a polyphenol from Curcuma longa, is...

Alejandra Castelló-Guillen, Marta Garrido-Reig, Jordi Caplliure-Llopis et al. · Pharmaceuticals · 0 citations

Review Sep 2026

Nose-to-Brain Delivery of Polyherbal Nanoformulations in Neurodegenerative Disorders: Translational Strategies and Challenges

The current knowledge on polyherbal synergy, nanocarrier-based targeting methods, and nose-to-brain delivery strategies to treat neurodegenerative disorders are summarized, highlighting their potential therapeutic applications, underlying mechanisms, translational issues, regulatory factors, and emerging trends such as...

Mahalakshmi Seelam, Varalakshmi Sagili · Drug Delivery Letters · 0 citations

Review Sep 2026

Curcumin nanoformulations for modulating neuroinflammation and oxidative stress in Alzheimer's disease: blood-brain barrier transport, formulation strategies and therapeutic applications.

Collectively, nanocarrier-mediated curcumin delivery represents a promising pharmaceutical strategy to improve brain-specific bioavailability and enable effective multitarget therapeutic intervention in AD.

M. Begum, Manickam Rajkumar, Prabha Govindaraj et al. · InflammoPharmacology · 1 citation

Review Sep 2026

Solid and Nanostructured Lipid Carriers for Plant-Derived Neuroprotective Agents: Advances and Future Perspectives.

Neurodegenerative disorders, particularly Alzheimer's disease (AD) and Parkinson's disease (PD), continue to pose a substantial therapeutic challenge, largely due to progressive neuronal degeneration and the limited effectiveness of currently available treatments. Plant-derived bioactive compounds-including polyphenols...

E. Küpeli, Methiye Mancak, Egemen Çakırlı et al. · Current pharmaceutical desig... · 0 citations

Review Aug 2026

Nanotechnology-enabled delivery of bioactive compounds for neuroprotection in Parkinson's disease: mechanisms and future directions.

This approach aims not only to control symptoms but also to potentially control neurodegeneration in PD, and the major challenges include large-scale production, long-term safety assessment, regulatory challenges, and site-specific delivery.

P. Gaur, Prachee Raje Bisht, Sonia Lal Gupta · Journal of Biomaterials Scie... · 0 citations

Review Open access Sep 2026

Applications of Prussian blue nanoparticles in the treatment of neurodegenerative diseases.

Neurodegenerative disorders, including Alzheimer's and Parkinson's diseases, are characterized by progressive neuronal dysfunction associated with oxidative stress, chronic neuroinflammation, mitochondrial impairment, and pathological protein aggregation. Despite advances in symptomatic treatments, effective disease-mo...

M. Busquets, R. Sabaté, Irene Álvarez-Berbel et al. · Nanomedicine · 0 citations